{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:57:16Z","timestamp":1781308636100,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005942","name":"Funda\u00e7\u00e3o Butantan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018798","name":"Instituto Butantan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018798","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/11946\\u20139"],"award-info":[{"award-number":["2021\/11946\\u20139"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2024\/06260\\u20139"],"award-info":[{"award-number":["2024\/06260\\u20139"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2020\/05264-0"],"award-info":[{"award-number":["2020\/05264-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/22780-6"],"award-info":[{"award-number":["2016\/22780-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128406","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:10:41Z","timestamp":1773065441000},"page":"128406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Non-clinical analysis of virus-like particles (VLP) containing SARS-CoV-2 vaccine antigens"],"prefix":"10.1016","volume":"79","author":[{"given":"Luis Giovani Oliveira","family":"Guardalini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Mancini","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaissa Consoni","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner","family":"Quintilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaio Moraes","family":"de Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraia Attie Calil","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durvanei Augusto","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128406_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.131324","article-title":"An unprecedented global challenge, emerging trends and innovations in the fight against COVID-19: a comprehensive review","volume":"267","author":"Moneshwaran","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.vaccine.2026.128406_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.envadv.2022.100328","article-title":"Impact assessment of COVID-19 global pandemic on water, environment, and humans","volume":"11","author":"Raza","year":"2023","journal-title":"Environ Adv"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128406_bb0250","doi-asserted-by":"crossref","first-page":"9699","DOI":"10.3390\/su14159699","article-title":"Socio-economic impacts and challenges of the coronavirus pandemic (COVID-19): an updated review","volume":"14","author":"Saniuk","year":"2022","journal-title":"Sustainability"},{"key":"10.1016\/j.vaccine.2026.128406_bb0045","unstructured":"COVID-19 cases | WHO COVID-19 dashboard. (n.d.). Retrieved August 3, 2024, from https:\/\/data.who.int\/dashboards\/covid19\/cases?n=o."},{"issue":"11","key":"10.1016\/j.vaccine.2026.128406_bb0120","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jiph.2020.07.019","article-title":"Epidemiologic surveillance for controlling Covid-19 pandemic: types, challenges and implications","volume":"13","author":"Ibrahim","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.vaccine.2026.128406_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijso.2023.100625","article-title":"Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -an overview of current evidence and counteracting strategies","volume":"55","author":"Sah","year":"2023","journal-title":"Int J Surg Open"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128406_bb0300","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular architecture of the SARS-CoV-2 virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128406_bb0110","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-virology-093022-013037","article-title":"The emergence and evolution of SARS-CoV-2","author":"Holmes","year":"2024","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.vaccine.2026.128406_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.605236","article-title":"Structural characterization of SARS-CoV-2: where we are, and where we need to be","volume":"7","author":"Mariano","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128406_bb0190","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/joim.13606","article-title":"Evaluation of SARS-CoV-2 antibody levels on hospital admission as a correlate of protection against mortality","volume":"293","author":"Mink","year":"2023","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128406_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275699","article-title":"The impact of COVID-19 vaccination in the US: averted burden of SARS-COV-2-related cases, hospitalizations and deaths","volume":"18","author":"Yamana","year":"2023","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128406_bb0030","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3390\/biom11081072","article-title":"Platforms for production of protein-based vaccines: from classical to next-generation strategies","volume":"11","author":"Cid","year":"2021","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128406_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149187","article-title":"SARS-CoV-2 vaccines: a triumph of science and collaboration","volume":"6","author":"Golob","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128406_bb0235","first-page":"30","article-title":"New generation vaccines for COVID-19 based on peptide, viral vector, artificial antigen presenting cell, DNA or mRNA","volume":"14","author":"Rezaei","year":"2022","journal-title":"Avicenna Journal of Medical Biotechnology"},{"key":"10.1016\/j.vaccine.2026.128406_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128406_bb0280","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.vaccine.2020.11.054","article-title":"New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates","volume":"39","author":"Ura","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128406_bb0185","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/14760584.2022.2029415","article-title":"Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines","volume":"21","author":"McFall-Boegeman","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128406_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2026.128406_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2023.100695","article-title":"Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering","volume":"21","author":"Cui","year":"2024","journal-title":"Immuno-Oncology and Technology"},{"key":"10.1016\/j.vaccine.2026.128406_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01100","article-title":"Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs","volume":"11","author":"Zepeda-Cervantes","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128406_bb0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/bit.26890","article-title":"Synthetic biology for bioengineering virus-like particle vaccines","volume":"116","author":"Charlton Hume","year":"2019","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128406_bb0225","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ymeth.2012.01.004","article-title":"Simultaneous expression of recombinant proteins in the insect cell-baculovirus system: production of virus-like particles","volume":"56","author":"Palomares","year":"2012","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128406_bb0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1586\/erv.12.153","article-title":"Insect cells as a production platform of complex virus-like particles","volume":"12","author":"Fernandes","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128406_bb0150","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2026.128406_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-27216-0_12","article-title":"Fundamentals of Baculovirus expression and applications","volume":"896","author":"Kost","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128406_bb0255","article-title":"A review of virus-like particle-based SARS-CoV-2 vaccines in clinical trial phases","volume":"21","author":"Sharifzadeh","year":"2022","journal-title":"Iranian Journal of Pharmaceutical Research\u00a0: IJPR"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128406_bb0135","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/vaccines10050786","article-title":"Chimeric virus-like particle-based COVID-19 vaccine confers strong protection against SARS-CoV-2 viremia in K18-hACE2 mice","volume":"10","author":"Kaewborisuth","year":"2022","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128406_bb0145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.vaccine.2013.11.036","article-title":"One-shot vaccination with an insect cell-derived low-dose influenza a H7 virus-like particle preparation protects mice against H7N9 challenge","volume":"32","author":"Klausberger","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128406_bb0260","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3390\/v14050914","article-title":"SARS-CoV-2 virus-like particles produced by a single recombinant Baculovirus generate anti-S antibody and protect against variant challenge","volume":"14","author":"Sullivan","year":"2022","journal-title":"Viruses"},{"issue":"42","key":"10.1016\/j.vaccine.2026.128406_bb0265","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1016\/j.vaccine.2015.08.090","article-title":"Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells","volume":"33","author":"Suphatrakul","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128406_bb0035","doi-asserted-by":"crossref","unstructured":"Cohen, A. A., van Doremalen, N., Greaney, A. J., Andersen, H., Sharma, A., Starr, T. N., Keeffe, J. R., Fan, C., Schulz, J. E., Gnanapragasam, P. N. P., Kakutani, L. M., West, A. P., Saturday, G., Lee, Y. E., Gao, H., Jette, C. A., Lewis, M. G., Tan, T. K., Townsend, A. R., \u2026 Bjorkman, P. J. (2022). Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science, 377(6606). Doi: https:\/\/doi.org\/10.1126\/SCIENCE.ABQ0839;REQUESTEDJOURNAL:JOURNAL:SCIENCE;CTYPE:STRING:JOURNAL.","DOI":"10.1126\/science.abq0839"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128406_bb0130","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/pbi.13813","article-title":"Plant-based expression and characterization of SARS-CoV-2 virus-like particles presenting a native spike protein","volume":"20","author":"Jung","year":"2022","journal-title":"Plant Biotechnol J"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128406_bb0140","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/vaccines10050786","article-title":"Chimeric virus-like particle-based COVID-19 vaccine confers strong protection against SARS-CoV-2 viremia in K18-hACE2 mice","volume":"10","author":"Kaewborisuth","year":"2022","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128406_bb0290","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nature Medicine"},{"issue":"SUPPL","key":"10.1016\/j.vaccine.2026.128406_bb0285","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jip.2011.05.004","article-title":"Large-scale production and purification of VLP-based vaccines","volume":"107","author":"Vicente","year":"2011","journal-title":"J Invertebr Pathol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128406_bb0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2144\/000113238","article-title":"A rapid method for titrating baculovirus stocks using the Sf-9 easy titer cell line","volume":"47","author":"Hopkins","year":"2009","journal-title":"BioTechniques"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128406_bb0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/imr.12863","article-title":"The 3Ds in virus-like particle based-vaccines: \u201cdesign, delivery and dynamics.\u201d","volume":"296","author":"Mohsen","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2026.128406_bb0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128406_bb0240","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/all.15311","article-title":"Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern","volume":"77","author":"Rothen","year":"2022","journal-title":"Allergy"},{"issue":"35","key":"10.1016\/j.vaccine.2026.128406_bb0080","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2021.07.034","article-title":"An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity","volume":"39","author":"Fluckiger","year":"2021","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2026.128406_bb0170","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2011.06.111","article-title":"Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128406_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.732998","article-title":"Functional severe acute respiratory syndrome coronavirus 2 virus-like particles from insect cells","volume":"12","author":"Naskalska","year":"2021","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128406_bb0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/vim.2018.0150","article-title":"Eosinophils and respiratory viruses","volume":"32","author":"Flores-Torres","year":"2019","journal-title":"Viral Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128406_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2020.04.021","article-title":"Eosinophil responses during COVID-19 infections and coronavirus vaccination","volume":"146","author":"Lindsley","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128406_bb0215","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.4049\/jimmunol.171.8.3977","article-title":"Expression and function of toll-like receptors in eosinophils: activation by toll-like receptor 7 ligand","volume":"171","author":"Nagase","year":"2003","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.vaccine.2026.128406_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106717","article-title":"Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses","volume":"86","author":"Gupta","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2026.128406_bb0100","article-title":"Mechanisms of stimulation of the immune response by aluminum adjuvants","volume":"20","author":"HogenEsch","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128406_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-47450-x","article-title":"Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus","volume":"15","author":"Dillard","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128406_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3827","article-title":"A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection","volume":"8","author":"Iwata-Yoshikawa","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2026.128406_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01673","article-title":"Prefusion RSV F immunization elicits Th2-mediated lung pathology in mice when formulated with a Th2 (but not a Th1\/Th2-balanced) adjuvant despite complete viral protection","volume":"11","author":"Eichinger","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128406_bb0005","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016175","article-title":"The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles","volume":"296","author":"Boson","year":"2021","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128406_bb0210","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.bpj.2021.01.012","article-title":"Elucidation of interactions regulating conformational stability and dynamics of SARS-CoV-2 S-protein","volume":"120","author":"Mori","year":"2021","journal-title":"Biophys J"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128406_bb0010","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.vaccine.2008.02.063","article-title":"Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection","volume":"26","author":"Bungener","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128406_bb0015","doi-asserted-by":"crossref","unstructured":"Cao, H., Yang, S., Wang, Y., Luan, N., Yin, X., Lin, K., & Liu, C. (2021). An established Th2-oriented response to an alum-adjuvanted SARS-CoV-2 subunit vaccine is not reversible by sequential immunization with nucleic acid-adjuvanted Th1-oriented subunit vaccines. Vaccines, 9(11). Doi: https:\/\/doi.org\/10.3390\/VACCINES9111261.","DOI":"10.3390\/vaccines9111261"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128406_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030420","article-title":"Analytical insights into protein\u2013alum interactions and their impact on conformational epitope","volume":"16","author":"Corrado","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128406_bb0105","first-page":"51","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"Npj vaccines 2018 3:1"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128406_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12101187","article-title":"Basic properties and development status of aluminum adjuvants used for vaccines","volume":"12","author":"Lan","year":"2024","journal-title":"Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128406_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/v16121932","article-title":"Development and evaluation of a Newcastle disease virus-like particle vaccine expressing SARS-CoV-2 spike protein with protease-resistant and stability-enhanced modifications","volume":"16","author":"Chen","year":"2024","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128406_bb0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128406_bb0175","first-page":"468","article-title":"The effect of COVID-19 vaccines on sperm parameters: a systematic review and meta-analysis","volume":"25","author":"Ma","year":"2023","journal-title":"Asian J Androl"},{"key":"10.1016\/j.vaccine.2026.128406_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.reprotox.2021.11.006","article-title":"Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19","volume":"107","author":"Dub\u00e9","year":"2022","journal-title":"Reproductive Toxicology (Elmsford, N.Y.)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:47:00Z","timestamp":1781308020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":61,"alternative-id":["S0264410X26002148"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128406","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-clinical analysis of virus-like particles (VLP) containing SARS-CoV-2 vaccine antigens","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128406"}}